BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.
Часто задаваемые вопросы
В каком секторе работает BRIM Biotechnology, Inc. (6885)?
BRIM Biotechnology, Inc. относится к сектору Прочее.
Какова текущая цена акций BRIM Biotechnology, Inc. (6885)?
По последним данным, цена акций BRIM Biotechnology, Inc. составляет 20,30 NT$, предыдущее закрытие — 20,30 NT$.
Выплачивает ли BRIM Biotechnology, Inc. (6885) дивиденды?
Нет, BRIM Biotechnology, Inc. не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у BRIM Biotechnology, Inc. (6885)?
У компании BRIM Biotechnology, Inc. бета 0.758, что указывает на более низкую волатильность по сравнению с рынком в целом.
